

CITATION REPORT

List of articles citing

Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease

DOI: 10.1111/liv.13587
Liver International, 2018, 38, 695-705.

Source: <https://exaly.com/paper-pdf/69641221/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
59	Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. <i>Scientific Reports</i> , 2018 , 8, 6789	4.9	47
58	Weight Loss Induced by Bariatric Surgery Restricts Hepatic Expression. <i>Journal of Obesity</i> , 2018 , 2018, 7108075	3.7	5
57	Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018 , 6, 317-325	5.2	19
56	Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. <i>Frontiers in Endocrinology</i> , 2018 , 9, 485	5.7	30
55	Elucidation of the Metabolic and Transcriptional Responses of an Oriental Herbal Medicine, Bangpungtongseong-san, to Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Mice. <i>Journal of Medicinal Food</i> , 2019 , 22, 928-936	2.8	3
54	GDF15 is an epithelial-derived biomarker of idiopathic pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019 , 317, L510-L521	5.8	25
53	Plasma FGF-21 and GDF-15 are elevated in different inherited metabolic diseases and are not diagnostic for mitochondrial disorders. <i>Journal of Inherited Metabolic Disease</i> , 2019 , 42, 918-933	5.4	19
52	The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China. <i>BMC Infectious Diseases</i> , 2019 , 19, 878	4	9
51	Building mass to prevent non-alcoholic fatty liver disease?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019 , 8, 173-176	2.1	0
50	Growth differentiation factor 15: A novel biomarker with high clinical potential. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019 , 56, 333-350	9.4	33
49	Implications of Mitochondrial Unfolded Protein Response and Mitokines: A Perspective on Fatty Liver Diseases. <i>Endocrinology and Metabolism</i> , 2019 , 34, 39-46	3.5	18
48	Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases. <i>Pharmacology & Therapeutics</i> , 2019 , 198, 46-58	13.9	57
47	Inter-organ cross-talk in metabolic syndrome. <i>Nature Metabolism</i> , 2019 , 1, 1177-1188	14.6	53
46	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
45	Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets. <i>Trends in Endocrinology and Metabolism</i> , 2020 , 31, 939-951	8.8	22
44	Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. <i>BioMed Research International</i> , 2020 , 2020, 5162541	3	0
43	Mitochondrial disorders due to mutations in the mitochondrial genome. 2020 , 401-413		

42	Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
41	Saturated Fatty Acids Promote GDF15 Expression in Human Macrophages through the PERK/eIF2/CHOP Signaling Pathway. <i>Nutrients</i> , 2020 , 12,	6.7	7
40	The GDF15-GFRAL Pathway in Health and Metabolic Disease: Friend or Foe?. <i>Annual Review of Physiology</i> , 2021 , 83, 127-151	23.1	18
39	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. <i>SSRN Electronic Journal</i> ,	1	
38	Growth differentiation factor 15: an emerging diagnostic biomarker of liver fibrosis in chronic hepatitis C patients. <i>Egyptian Liver Journal</i> , 2021 , 11, 6	1.6	
37	Effects of Exercise Intervention on Mitochondrial Stress Biomarkers in Metabolic Syndrome Patients: A Randomized Controlled Trial. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
36	Gene Expression Profiles Reveal Extracellular Matrix and Inflammatory Signaling in Radiation-Induced Premature Differentiation of Human Fibroblast. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 539893	5.7	1
35	GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021 , 1865, 129834	4	4
34	TFEB-GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response. <i>Nature Metabolism</i> , 2021 , 3, 410-427	14.6	14
33	Hepatocardiac or Cardiohepatic Interaction: From Traditional Chinese Medicine to Western Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021 , 2021, 6655335	2.3	4
32	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1443-1451	3.4	0
31	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. <i>Med</i> , 2021 , 2, 836-850.e10	31.7	3
30	GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 592-607	15.2	24
29	Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2021 ,	4.8	0
28	Stress-induced FGF21 and GDF15 in obesity and obesity resistance. <i>Trends in Endocrinology and Metabolism</i> , 2021 , 32, 904-915	8.8	6
27	Management of non-alcoholic fatty liver disease in patients with sarcopenia. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-13	4	
26	Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. <i>Bioscience Reports</i> , 2020 , 40,	4.1	7
25	Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2391-2407	15.9	14

24	Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study. <i>Gut and Liver</i> , 2019 , 13, 67-76	4.8	37
23	Health benefits attributed to 17 β -estradiol, a lifespan-extending compound, are mediated through estrogen receptor α . <i>ELife</i> , 2020 , 9,	8.9	13
22	Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. <i>Nutrition and Diabetes</i> , 2021 , 11, 32	4.7	3
21	It's Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging. <i>Gut and Liver</i> , 2019 , 13, 5-6	4.8	
20	Health benefits attributed to 17 β -estradiol, a lifespan-extending compound, are mediated through estrogen receptor α		
19	Factors Mediating Exercise-induced Organ Crosstalk.. <i>Acta Physiologica</i> , 2022 , e13766	5.6	2
18	Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
17	GDF-15, a future therapeutic target of glucolipid metabolic disorders and cardiovascular disease.. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 146, 112582	7.5	2
16	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. <i>Livers</i> , 2022 , 2, 30-76		1
15	Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity.. <i>Nutrition and Diabetes</i> , 2022 , 12, 9	4.7	0
14	Effect of GDF15 on acetaminophen (APAP)-induced liver injury in mice.		
13	Heightened levels of plasma growth differentiation factor 15 in men living with HIV.. <i>Physiological Reports</i> , 2022 , 10, e15293	2.6	0
12	Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.. <i>Redox Biology</i> , 2022 , 52, 102322	11.3	1
11	Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis. <i>Scientific Reports</i> , 2022 , 12,	4.9	
10	Cell non-autonomous effect of hepatic growth differentiation factor 15 on the thyroid gland. 13,		
9	A mouse model of human mitofusin 2-related lipodystrophy exhibits adipose-specific mitochondrial stress and reduced leptin secretion.		0
8	Knocking on GDF15's door for the treatment of type 2 diabetes mellitus. 2022 ,		0
7	A Sequential Machine Learning Model for Identifying At-risk NASH by Combining Liver Stiffness Measurement and Protein Biomarkers.		0

- 6 Circulating Adipokines and Hepatokines Serve as Diagnostic Markers during Obesity Therapy. **2022**, 23, 14020
- 5 GDF15 in Vascular and Liver Metabolic Disorders: A Novel Therapeutic Target. **2022**, 16, 55-59
- 4 Interaction between Sarcopenia and NAFLD.
- 3 Growth differentiation factor 15 is dispensable for acetaminophen-induced liver injury in mice.
- 2 A mouse model of human mitofusin-2-related lipodystrophy exhibits adipose-specific mitochondrial stress and reduced leptin secretion. 12,
- 1 The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease. 10,